BMX-001:
Enhance Tumor Response, Reduce Side Effects.
How BMX-001 uses redox biology to enhance tumor response while protecting healthy tissue.
Reduces angiogenesis and tumor adaptation via hypoxia-associated signaling — preclinical EMSA data with a close structural analog (MnTE-2-PyP) demonstrate reduced HIF-1 transcription-factor binding to DNA12
HIF-1α signaling is not active in healthy tissue. Instead, the molecule's redox cycling there supports endogenous antioxidant defenses — protecting normal cells from radiation-induced oxidative injury without shielding the tumor
Modulates NF-κB-mediated inflammatory and pro-survival signaling, including downstream cytokine and anti-apoptotic pathways — preclinical EMSA data with a close structural analog (MnTE-2-PyP) demonstrate reduced NF-κB DNA binding13
Reduces the inflammatory cytokine cascade — reducing chemoradiation-induced tissue injury
Expanding the dose-response window
By inhibiting HIF-1α to sensitize tumor cells and NF-κB to protect normal tissue, BMX-001 is designed to widen the gap between tumor control and complications — expanding the therapeutic ratio without escalating radiation dose.
Better tumor control without escalating radiation or chemotherapy doses
Evaluated in combination with radiation and standard chemotherapies, including cisplatin and temozolomide; preclinical data also reveal immune-based radiosensitization mechanisms relevant to immunotherapy
A single agent targeting core pathways that enhance tumor response and protect normal tissue.
Claims on this page are supported by published literature, scientific presentations, regulatory information, and BioMimetix data on file, as indicated.
One molecule.
Two important actions.
BMX-001 is a redox-active manganese porphyrin (MnP) that mimics the activity of superoxide dismutase (SOD), an endogenous antioxidant enzyme. Its redox-active manganese center responds differently to the distinct redox environments of tumor and normal tissue, sensitizing tumor cells to radiation and chemotherapy while protecting normal tissue from oxidative injury16.
Normal Tissue Protection2
In healthy tissue its SOD-mimetic activity scavenges superoxide and blunts the inflammatory cytokine cascade, reducing chemoradiation-induced mucositis, dermatitis, and GI injury.
Therapeutic Ratio Expansion
The dual action is designed to widen the therapeutic window — enhanced tumor response with reduced normal-tissue toxicity — without escalating radiation or chemotherapy dose.
Broad distribution,
lasting retention, favorable safety.
A subcutaneously administered small molecule with favorable pharmacokinetics — rapid plasma clearance paired with prolonged tissue retention, broad distribution including the blood–brain barrier, and a well-tolerated safety profile across more than 180 patients treated to date.
Data on file, BioMimetix. BMX-001 is an investigational product; safety and efficacy have not been established by the FDA.
Both effects. Observed together.
Early evidence across these programs suggests both effects may occur together — enhanced tumor response alongside reduced normal-tissue toxicity, observed in the same patients across three cancer types. This is the therapeutic-ratio profile BMX-001 is designed to deliver2418.
Tumor response observed alongside full chemoradiation dosing
lower rate of severe oral mucositis observed vs the historical control (ROMAN)
Encouraging median OS of 31.3 months observed with BMX-001 + SOC vs 24.7 months with SOC alone (Randomized Phase 2, N=160)
No added neurotoxicity observed — patients were able to complete chemoradiation on schedule with improved quality of life observed
Currently being evaluated alongside standard chemoradiation dosing
Lower rate of dermatitis & GI injury observed